Dianthus 7.3M share Secondary priced at $81.00

By TheFly | March 11, 2026, 6:05 AM

The deal size was increased to $625M in common stock from $400M in common stock. Jefferies, Evercore ISI, Stifel, Guggenheim and William Blair acted as joint book running managers for the offering.

Claim 70% Off TipRanks Premium

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on DNTH:

Disclaimer & Disclosure Report an Issue

Mentioned In This Article

DNTH

+0.95%

Dianthus Therapeutics Inc

Latest News

Sep-04	UiPath downgraded, Shell upgraded: Wall Street's top analyst calls DNTH The Fly
Sep-02	Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) DNTH GlobeNewswire
Sep-01	Dianthus Therapeutics to Participate in Three Investor Conferences During September DNTH GlobeNewswire
Aug-10	Dick's Sporting Goods shares rise after Wells Fargo upgrade DNTH InvestorsHub
Aug-04	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results DNTH GlobeNewswire
Aug-04	Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases DNTH GlobeNewswire
Aug-03	Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) DNTH GlobeNewswire
Jul-02	Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4) DNTH GlobeNewswire
Jun-29	Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis DNTH GlobeNewswire
Jun-12	DNTH Stock Clocks Best Day In Over 3 Months On Strong Nerve Disorder Study Results DNTH +7.35% Stocktwits
Jun-10	Sanofi, An Argenx Rival, Bites The Dust - But A Third Biotech Took The Biggest Hit DNTH -9.64% Investor's Business Daily
Jun-02	Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) DNTH -8.81% GlobeNewswire
May-26	Dianthus Therapeutics to Participate in Two Investor Conferences DNTH GlobeNewswire
May-05	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results DNTH GlobeNewswire
May-01	Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) DNTH GlobeNewswire

Dianthus 7.3M share Secondary priced at $81.00

Claim 70% Off TipRanks Premium

Mentioned In This Article

Latest News

Upgrade your Finviz experience